Life-saving vaccine developed at University of Houston heads to human clinical trials

green light

Colin Haile, a research associate professor of psychology at UH, serves as scientific co-founder and adviser at the New York health tech startup that's licensing the Fentanyl overdose vaccine he created. Photo via UH.edu

Fentanyl kills nearly 200 Americans each day, but Houston researchers have developed a vaccine to prevent users from succumbing to an overdose.

Last week, a New York-based startup, OVAX Incorporated, announced that it has licensed that intellectual property and $10 million to commercialize that research.

The discovery of the vaccine comes out of the University of Houston lab of Colin Haile, a research associate professor of psychology at UH and the Texas Institute for Measurement, Evaluation and Statistics (TIMES), as well as a founding member of the UH Drug Discovery Institute. The vaccine will be marketed under the name Fentanyl Armour.

“We believe Fentanyl Armour could have a significant impact on a very serious problem plaguing society for years – opioid misuse,” says Haile, who serves as scientific co-founder and adviser at OVAX, in a press release.

Human trials are set to start as soon as the beginning of 2025.

“This breakthrough discovery could have major implications for the nation’s opioid epidemic by becoming a relapse prevention agent for people trying to quit using opioids,” adds Haile.

In fact, 80 percent of patients with opioid use disorder (OUD) will eventually relapse. Fentanyl Armour could become a landmark addition to our country’s fight against addiction.

From Your Site Articles
UH has announced a new multi-disciplinary institute to promote drug discovery. Photo courtesy of UH

University of Houston launches new institute to promote drug discovery research

New to hou

The University of Houston has introduced a new institute to its campus. The multi-disciplinary program includes both on-campus and citywide collaboration.

UH has established the Drug Discovery Institute in order to streamline and modernize drug discovery. In partnership with the Texas Medical Center, as well as other organizations, the DDI will tap into technology and innovation to advance modern medicine. The institute will collaborate with the UH colleges of Pharmacy, Natural Sciences and Mathematics and Cullen College of Engineering.

"Our new Drug Discovery Institute could not have been launched at a more appropriate juncture. With the frantic quest for effective drugs to counter the current and future viral infections, the broad and deep strength of the University of Houston is being brought to bear and will no doubt advance the development of innovative cures," says Amr Elnashai, vice president for research and technology transfer, in a press release.

The university currently has about 100 faculty members conducting drug discovery-related research, but, according to the release, these efforts have been fragmented. With DDI, UH hopes to bring these efforts together under one roof in order to promote synergistic research.

F. Lamar Pritchard, dean of the UH College of Pharmacy, has been advocating for the idea of a collaborative drug discovery research center for more than a decade

"The breadth of this initiative will establish the institute and the University among the national leaders in drug discovery and become one of the first to fully embrace AI into its academic drug discovery programs," Pritchard says in the release.

The new institute will be led by Ruiwen Zhang, Robert L. Boblitt Endowed Professor in Drug Discovery at the College of Pharmacy,. He will hold the position of director for two years, before the title rotates through the collaboration of colleges.

"Working together is critical, none of us can do this alone," Zhang says in the release. "In drug discovery, a chemist needs a biologist, a biologist needs a pharmacologist, and so on. We will build a platform and infrastructure, along with the necessary tools, to bring everyone together."

The facility will work to promote each of the school's expertise across many aspects of the drug discovery process — including high-throughput screening technologies, organ-on-chip models, biosensing and biofeedback, molecular modeling and more.

"Practicing team science is key to making innovative discoveries and we are eager to collaborate with faculty across the University to develop cutting-edge research and ultimately to find treatments and cures for disease," says Dan Wells, dean of the College of Natural Sciences and Mathematics, in the release.

Additionally, DDI will offer seed grants for interdependent drug-discovery projects and encourage collaboration and the sharing of data with experts around the world

"I foresee one day in the near future that we are able to create some of the strongest databases and artificial intelligence approaches to drug discovery," Pritchard says in the release. "Rather than having to screen millions of compounds to find one therapy, we may be able to narrow that down to 1,000 and really streamline the process."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas university's innovative 'WaterHub' will dramatically reduce usage by 40%

Sustainable Move

A major advancement in sustainability is coming to one Texas university. A new UT WaterHub at the University of Texas at Austin will be the largest facility of its kind in the U.S. and will transform how the university manages its water resources.

It's designed to work with natural processes instead of against them for water savings of an estimated 40 percent. It's slated for completion in late 2027.

The university has had an active water recovery program since the 1980s. Still, water is becoming an increasing concern in Austin. According to Texas Living Waters, a coalition of conservation groups, Texas loses enough water annually to fill Lady Bird Lake roughly 89 times over.

As Austin continues to expand and face water shortages, the region's water supply faces increased pressure. The UT WaterHub plans to address this challenge by recycling water for campus energy operations, helping preserve water resources for both the university and local communities.

The 9,600-square-foot water treatment facility will use an innovative filtration approach. To reduce reliance on expensive machinery and chemicals, the system uses plants to naturally filter water and gravity to pull it in the direction it needs to go. Used water will be gathered from a new collection point near the Darrell K Royal Texas Memorial Stadium and transported to the WaterHub, located in the heart of the engineering district. The facility's design includes a greenhouse viewable to the public, serving as an interactive learning space.

Beyond water conservation, the facility is designed to protect the university against extreme weather events like winter storms. This new initiative will create a reliable backup water supply while decreasing university water usage, and will even reduce wastewater sent to the city by up to 70 percent.

H2O Innovation, UT’s collaborator in this project, specializes in water solutions, helping organizations manage their water efficiently.

"By combining cutting-edge technology with our innovative financing approach, we’re making it easier for organizations to adopt sustainable water practices that benefit both their bottom line and the environment, paving a step forward in water positivity,” said H2O Innovation president and CEO Frédéric Dugré in a press release.

The university expects significant cost savings with this project, since it won't have to spend as much on buying water from the city or paying fees to dispose of used water. Over the next several years, this could add up to millions of dollars.

---

A version of this story originally appeared on our sister site, CultureMap Austin.

Texas female-founded companies raised more than $1 billion in 2024, VC data shows

by the numbers

Female-founded companies in Dallas-Fort Worth may rack up more funding deals and more money than those in Houston. However, Bayou City beats DFW in one key category — but just barely.

Data from PitchBook shows that in the past 16 years, female-founded companies in DFW collected $2.7 billion across 488 deals. By comparison, female-founded companies in the Houston area picked up $1.9 billion in VC through 343 deals.

Yet if you do a little math, you find that Houston ekes out an edge over DFW in per-deal values. During the period covered by the PitchBook data, the value of each of the DFW deals averaged $5.53 million. But at $5,54 million, Houston was just $6,572 ahead of DFW for average deal value.

Not surprisingly, the Austin area clobbered Houston and DFW.

During the period covered by the PitchBook data, female-founded companies in the Austin area hauled in $7.5 billion across 1,114 deals. The average value of an Austin deal: more than $6.7 million.

Historically, funding for female-established companies has lagged behind funding for male-established companies. In 2024, female-founded companies accounted for about one-fourth of all VC deals in the U.S., according to PitchBook.

PitchBook noted that in 2024, female-founded companies raised $38.8 billion, up 27 percent from the previous year, but deal count dropped 13.1 percent, meaning more VC for fewer startups. In Texas, female-founded companies brought in $1.3 billion last year via 151 deals. The total raised is the same as 2023, when Texas female founders got $1.3 billion in capital across 190 deals.

“The VC industry is still trying to find solid footing after its peak in 2021. While some progress was made for female founders in 2024, particularly in exit activity, female founders and investors still face an uphill climb,” says Annemarie Donegan, senior research analyst at PitchBook.

Here are 3 Houston innovators to know right now

Innovators to Know

Editor's note: These Houston innovators are making big strides in the fields of neurotechnology, neurodevelopmental diagnosis, and even improving the way we rest and recharge.

For our latest roundup of Innovators to Know, we meet a researcher who is working with teams in Houston and abroad to develop an innovative brain implant; a professor who has created an AI approach to diagnosis; and a local entrepreneur whose brand is poised for major expansion in the coming years.

Jacob Robinson, CEO of Motif Neurotech

Houston startup Motif Neurotech has been selected by the United Kingdom's Advanced Research + Invention Agency (ARIA) to participate in its inaugural Precision Neurotechnologies program. The program aims to develop advanced brain-interfacing technologies for cognitive and psychiatric conditions. Three Rice labs will collaborate with Motif Neurotech to develop Brain Mesh, which is a distributed network of minimally invasive implants that can stimulate neural circuits and stream neural data in real time. The project has been awarded approximately $5.9 million.

Motif Neurotech was spun out of the Rice lab of Jacob Robinson, a professor of electrical and computer engineering and bioengineering and CEO of Motif Neurotech.

Robinson will lead the system and network integration and encapsulation efforts for Mesh Points implants. According to Rice, these implants, about the size of a grain of rice, will track and modulate brain states and be embedded in the skull through relatively low-risk surgery. Learn more.

Dr. Ryan S. Dhindsa, Dhindsa Lab

Dr. Ryan S. Dhindsa, assistant professor of pathology and immunology at Baylor and principal investigator at the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and his team have developed an artificial intelligence-based approach that will help doctors to identify genes tied to neurodevelopmental disorders. Their research was recently published the American Journal of Human Genetics.

Dhindsa Lab uses “human genomics, human stem cell models, and computational biology to advance precision medicine.” The diagnoses that stem from the new computational tool could include specific types of autism spectrum disorder, epilepsy and developmental delay, disorders that often don’t come with a genetic diagnosis.

“Although researchers have made major strides identifying different genes associated with neurodevelopmental disorders, many patients with these conditions still do not receive a genetic diagnosis, indicating that there are many more genes waiting to be discovered,” Dhindsa says. Learn more.

Khaliah Guillory, Founder of Nap Bar

From nap research to diversity and inclusion, this entrepreneur is making Houston workers more productiveFrom opening Nap Bar and consulting corporations on diversity and inclusion to serving the city as an LGBT adviser, Khaliah Guillory is focused on productivity. Courtesy of Khaliah Guillory

Khalia Guillory launched her white-glove, eco-friendly rest sanctuary business, Nap Bar, in Houston in 2019 to offer a unique rest experience with artificial intelligence integration for working professionals, entrepreneurs and travelers who needed a place to rest, recharge and rejuvenate.

Now she is ready to take it to the next level, with a pivot to VR and plans to expand to 30 locations in three years.

Guillory says she’s now looking to scale the business by partnering with like-minded investors with experience in the wellness space. She envisions locations at national and international airports, which she says offer ripe scenarios for patrons needing to recharge. Additionally, Guillory wants to build on her initial partnership with UT Health by going onsite to curate rest experiences for patients, caregivers, faculty, staff, nurses and doctors. Colleges also offer an opportunity for growth. Learn more.

View All Listings